Neurocrine Biosciences (NBIX)

Executive Summary

Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its flagship product, Ingrezza (valbenazine), is a leading therapy for tardive dyskinesia, contributing to a strong commercial base. The company's pipeline includes advancing programs in schizophrenia, with NBI-1117568 in Phase 3 trials, and earlier-stage assets for conditions like congenital adrenal hyperplasia. Neurocrine's robust R&D platform and strategic collaborations position it for sustained growth. Key upcoming catalysts include Phase 3 data for NBI-1117568 in schizophrenia and potential label expansions for Ingrezza.

Upcoming Catalysts (preview)

• H2 2026NBI-1117568 Phase 3 Schizophrenia Data Readout60% success
• Q1 2027Ingrezza Label Expansion for Tourette Syndrome40% success
• TBDEarly-Stage Pipeline Updates (e.g., NBI-77860 for CAH)30% success